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Abstract
The aim of this work is to assess if cumulative dose (CD) and dose intensity 
(DI) of everolimus may affect survival of advanced pancreatic neuroendocrine 
tumors (PNETs) patients. One hundred and sixteen patients (62 males and 54 
females, median age 55 years) with advanced PNETs were treated with everoli-
mus for ≥3 months. According to a Receiver operating characteristics (ROC) 
analysis, patients were stratified into two groups, with CD ≤ 3000 mg (Group 
A; n = 68) and CD > 3000 mg (Group B; n = 48). The response rate and 
toxicity were comparable in the two groups. However, patients in group A 
experienced more dose modifications than patients in group B. Median OS was 
24 months in Group A while in Group B it was not reached (HR: 26.9; 95% 
CI: 11.0–76.7; P < 0.0001). Patients who maintained a DI higher than 9 mg/
day experienced a significantly longer OS and experienced a trend to higher 
response rate. Overall, our study results showed that both CD and DI of everoli-
mus play a prognostic role for patients with advanced PNETs treated with 
everolimus. This should prompt efforts to continue everolimus administration 
in responsive patients up to at least 3000 mg despite delays or temporary 
interruptions.
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Introduction
Pancreatic neuroendocrine tumors (PNETs) are still con-
sidered a rare disease which accounts for approximately 
10% of all cases of pancreatic cancer [1]. Nevertheless, 
the increasing incidence and prevalence of PNETs observed 
in the last four decades [2], together with the frequent 
delay in diagnosis [3, 4], have led to increasing interest 
in PNETs, with major advances in their treatment and 
management [5].
Among these advances, the elucidation of the high 
expression and activity of mammalian target of rapamycin 
(mTOR) in PNETs has led to the recognition of mTOR 
as an important therapeutic target [6]. The mTOR serine/
threonine protein kinase pathway plays a key role in cell 
growth and proliferation, angiogenesis, and nutrient uptake 
by increasing protein synthesis [7, 8]. A pathological acti-
vation of this pathway has been reported in a variety of 
cancers, including PNETs, with a primary role in tumo-
rigenesis [9]; therefore, strategies aimed at interfering with 
mTOR function could represent effective approaches in 
the targeted therapy of PNETs.
Based on the results of the phase III RADIANT- 3 trial 
[10], the oral mTOR inhibitor everolimus has become 
an established recommended standard therapy for patients 
with advanced PNETs. Although everolimus exerts a very 
selective action on a specific molecular target, this drug 
may be associated with a number of adverse effects, 
included stomatitis, rash, fatigue, pneumonitis, and meta-
bolic alterations mainly represented by hyperlipidemia. 
Other common events include abdominal pain, nausea 
and/or vomiting, anemia, increased serum creatinine level, 
liver function test abnormalities, dizziness, headache, and 
epistaxis [11–13]. These adverse effects frequently lead to 
modify the dosage by drug delay and/or reduction of 
dose, with a significant impact on cumulative dose (CD) 
and dose intensity (DI).
In this study, we aimed to evaluate the effect of CD 
and DI—defined as the total amount of everolimus taken 
by the patient despite delay or dose reductions and as 
drug dose delivered per time unit, respectively—on survival 
of patients treated with everolimus for unresectable or 
metastatic PNETs.
Patients and Methods
Patients
In this nonrandomized retrospective study, we included 
all the consecutive patients with advanced (unresectable 
or metastatic) PNETs treated with everolimus in 14 Italian 
institutions between December 2009 and December 2015. 
All the data were prospectively collected and retrospectively 
analyzed for the purpose of the study. Recorded patient 
characteristics and clinical features included the following: 
gender, age, neoplastic grading (by the Ki67 labeling index 
of the WHO 2010 classification [14]) and histological 
features, immunohistochemical staining for general neu-
roendocrine markers, stage of disease (T, N, M) at the 
time of the diagnosis (according to the TNM Seventh 
edition (2010) [15]), and data regarding all the treatments 
received by the patients.
Study design and treatment regimens
Everolimus was administered orally at a dose of 10 mg 
once daily in all patients with the exception of 11 patients 
who started with 5 mg daily. Treatment was continued 
until progression of the disease, development of unac-
ceptable toxicity or death. Doses were delayed or reduced 
if the patient experienced clinically relevant adverse events, 
according to standard guidelines and clinical practice.
Follow- up comprised regular history- taking, physical 
examination, and laboratory assessment (hematologic and 
serum chemical measurement) every week, and imaging 
studies through computed tomography (CT) or magnetic 
resonance imaging (MRI) every 8–12 weeks. Response to 
therapy was assessed according to the RECIST 1.1 (Response 
Evaluation Criteria In Solid Tumors) [16]. All assessments 
were confirmed at a central level.
CD was defined as the total amount of everolimus taken 
by the patient despite delay or dose reductions; DI was 
defined as everolimus dose delivered per time unit (mg/day) 
taken by the patient divided by the days of therapy (includ-
ing temporary interruptions).
Statistical analysis
Overall survival (OS) was defined as the interval between 
the initiation of everolimus- based treatment to death from 
any cause or to the last follow- up visit. Patients who were 
not reported as dead at the time of the analysis were 
censored at the date they were last known to be alive. 
Progression- free survival (PFS) was defined as the interval 
between the initiation of everolimus treatment and disease 
progression or death. Survival distribution was estimated 
by the Kaplan–Meier method. Significant differences in 
probability of surviving between the strata were evaluated 
by log- rank test. Receiver operating characteristics (ROC) 
curve analysis was performed to determine a cut off value 
for the CD of everolimus. The Cox multivariate propor-
tional hazard regression model was used to evaluate the 
effects of a number of factors on OS. A level of 0.05 was 
chosen to assess the statistical significance. Statistical analyses 
were performed using MedCalc version 11.4.4.0 (MedCalc 
Software, Broekstraat 52, 9030 Mariakerke, Belgium).
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Results
In total, 116 patients were evaluated. Median age was 
55 years old (range 19–89), and male/female ratio was 
62/54. As for grading determination, grading showed G2 
predominance (25% G1 and 75% G2). Twenty- eight 
patients died during follow- up (Table 1).
All patients received everolimus for advanced/metastatic 
PNETs. With respect to previous history, 110 patients 
presented with locally advanced or metastatic disease at 
diagnosis and 56 of them (48.3%) did not undergo surgi-
cal resection. Among the remaining 60 patients (51.7%), 
39 subjects (33.6%) had undergone debulking surgery and/
or metastasectomy, but presented with recurrent/progres-
sive disease when everolimus was started. Previous radical 
resection was performed in 21 patients (18.1%), all of 
them relapsed with liver metastases. Loco- regional therapies 
were performed in 23 patients: transarterial chemoembo-
lization as loco- regional therapy in 18 patients, radiofre-
quency in the remaining 5. Almost all patients (93.1%) 
received somatostatin analogs and 54 patients received 
peptide receptor radionuclide therapy (PRRT) (Table 1). 
Everolimus was administrated together with somatostatin 
analogs (SSas) in 82 patients, while 34 patients received 
the target therapy alone.
Table 2 presents the previous lines of therapies and 
summarizes the outcomes of everolimus therapy. All 
patients received everolimus for at least 3 months and 
only in twenty- two cases (19.0%) as first- line therapy.
Everolimus administration was temporarily interrupted 
in 77 patients (66.4%), with a median delay of 28 days, 
while 25 subjects (21.6%) underwent dose reduction espe-
cially from 10 mg down to 5 mg.
Positive response was observed in 97 patients (83.7%) 
while 11 patients (9.5%) experienced a clinical benefit, 
that is, an improvement in symptoms and quality of life. 
Eighty- three patients (71.6%) reported adverse effects 
while receiving study drug. The most common toxicities 
were stomatitis and mucositis, followed by hematological 
effects (grade 3 thrombocytopenia was observed in three 
patients who presented grade 1 thrombocytopenia at 
baseline, and grade 3 anemia occurred in 1 patient). 
Other reported events included diarrhea, fatigue, skin 
rash/acne, metabolic adverse events, and liver toxicity, 
and only one patient presented grade 3 hypertension. 
Grade 3 pneumonitis occurred in two patients and the 
adverse event was resolved by medical therapy with no 
sequelae in all cases.
Median PFS was 19 months (range: 3–71 months), while 
median OS was 44 months (range: 1–76 months).
According to everolimus cumulative dose (CD), patients 
were stratified in two groups with CD ≤ 3000 mg (Group 
A) and CD > 3000 mg (Group B). This cut- off, with 
the highest sensitivity and specificity for estimating the 
everolimus cumulative dose was set at 3000 mg after ROC 
curve analysis (Fig. 1). Groups A (n = 68) and B (n = 48) 
were homogeneous for main characteristics, including 
gender, age, grading, stage at initial diagnosis, response 
rate, grade 3–4 toxicity and all the patients received 
everolimus for at least 3 months.
Univariate analysis showed that line of therapy of 
everolimus (everolimus received as first line vs. everolimus 
received after 1 to 3 lines of chemotherapy, P = 0.045) 
and everolimus CD > 3000 mg (P = 0.04) were associ-
ated with a better OS.
At multivariate analysis, everolimus CD > 3000 mg 
resulted an independent prognostic factor both for OS 
[Hazard Ratio (HR): 0.16; 95% Confidence Interval (CI): 
0.06–0.41, P < 0.0001] and for PFS (HR: 0.56; 95% CI: 
0.34–0.92, P < 0.047).
Although the rate of best response and grade 3–4 toxic-
ity were comparable between the two groups, patients in 
group A experienced more dose modifications (delays or 
reductions according to medical decisions and patients’ 
preference) as compared with patients in group B. Median 
DI was 88.5% (range: 29.5–100%) in group A, while 
median DI was 96% in group B (range: 37–100%). Median 
OS was 24 months in Group A (range: 2–42 months), 
Table 1. Clinical- pathological characteristics, surgical, and medical his-
tory of the enrolled patients.
N (%)
Patients 116 (100.0)
Gender
Male 62 (53.5)
Female 54 (46.5)
Age — year median (range) 55 (19–89)
Histological grading
Ki67 < 3% (G1) 29 (25)
Ki67 3–20% (G2) 87 (75)
Stage at the initial diagnosis
Localized 6 (5.2)
Locally advanced 18 (15.5)
Metastatic 92 (79.3)
Surgery
Not performed 56 (48.3)
Performed 60 (51.7)
Debulking surgery and/or metastasectomy 39 (33.6)
Radical surgery 21 (18.1)
SSa
Not performed 8 (6.9)
Performed 108 (93.1)
PRRT
Not performed 62 (53.5)
Performed 54 (46.5)
Death
No 88 (75.9)
Yes 28 (24.1)
1496 © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
R. Berardi et al.Everolimus dose in PNETs
while in Group B it was not reached (HR: 26.9; 95% CI: 
11.0–76.7; P < 0.0001) (Fig. 2).
Furthermore, analysis of data showed that patients who 
maintained a DI higher than 9 mg/day experienced a 
significantly of longer OS and a trend to higher response 
rate, although not statistically significant. Median PFS was 
15 months (range: 0–57 months) in Group A and 
23 months (range: 0–71 months) in Group B, with a 
significant advantage for this latter group (HR: 1.85; 95% 
CI: 1.141–2.996; P = 0.0125) (Fig. 3).
Finally, patients were stratified into four groups:
1. neither dose reduction nor dose delay,
2. dose reduction only
3. dose delay only
4. dose reduction and dose delay.
N (%)
Carboplatin+Etoposide → PRRT → PRRT → Capecitabine 1 (16.6)
Gemcitabine → Capecitabine+Oxaliplatin → SSa → PRRT 1 (16.6)
SSa → Capecitabine+Temozolomide → PRRT → 
5- Fluorouracil+Oxaliplatin
1 (16.6)
Dose delay
No 39 (33.6)
Yes 77 (66.4)
Days of delay in patients with everolimus interruption
Median 28
Range 5–279
Dose reduction
No 91 (78.4)
Yes 25 (21.6)
Entity of reduction
From 10 mg to 5 mg 21/25 (18.1)
From 10 mg to 10 mg on alternate days 1/25 (0.9)
From 5 mg daily to 5 mg on alternate days 3/25 (2.7)
Response
Complete response (CR) 1 (0.9)
Partial response (PR) 11 (9.5)
Stable of disease (SD) 85 (73.3)
Progressive disease (PD) 19 (16.3)
Toxicity
No 33 (28.4)
Yes 83 (71.6)
Types of adverse reactions (G3- G4) (%)
Stomatitis and mucositis 5 (4.3)
Thrombocytopenia 5 (4.3)
Diarrhea 3 (2.6)
Metabolic adverse events (diabetes/hyperglycemia, 
dyslipidemia)
3 (2.6)
Fatigue 2 (1.7)
Pneumonitis 2 (1.7)
Anemia 1 (0.9)
Leukopenia with neutropenia 1 (0.9)
Skin rash/acne 1 (0.9)
Increased AST and/or ALT level 1 (0.9)
Hypertension 1 (0.9)
Table 2. (Continued)Table 2. Details of everolimus therapy in the overall population.
N (%)
Everolimus 116 (100.0)
Patients treated with first- line everolimus (administrated 
together with SSa in 17 patients)
22 (19.0)
Patients treated with second-line everolimus 
 (administrated together with SSa in 32 patients)
38 (32.8)
Prior treatments
SSa 32 (84.2)
PRRT 5 (13.2)
CHT 1 (2.6)
Cisplatin+5-Fluorouracil 1 (100.0)
Patients treated with third-line everolimus 
 (*administrated together with SSa in 26 patients)
38 (32.8)
Prior treatments
SSa 31 (81.6)
PRRT 24 (63.2)
Sunitinib 3 (7.9)
IFN 1 (2.6)
CHT 13 (34.2)
Cisplatin+Etoposide → PRRT 2 (15.3)
Cisplatin+Etoposide → Topotecan 1 (7.7)
Capecitabine+Oxaliplatin → SSa 1 (7.7)
Capecitabine → SSa 1 (7.7)
Gemcitabine+Oxaliplatin → Capecitabine 1 (7.7)
SSa → Capecitabine+Temozolomide 1 (7.7)
Cisplatin+Etoposide →SSa 1 (7.7)
SSa → Cisplatin+Etoposide 1 (7.7)
SSa → Capecitabine+Oxaliplatin 1 (7.7)
5- Fluorouracil → Capecitabine 1 (7.7)
Capecitabine → PRRT 1 (7.7)
Capecitabine+Oxaliplatin → Capecitabine 1 (7.7)
Patients treated with fourth-line everolimus 
 (administrated together with SSa in 4 patients)
12 (10.3)
Prior treatments
SSa 10 (83.3)
PRRT 9 (75.0)
CHT 12 (100.0)
SSa → PRRT → Capecitabine 2 (17.0)
SSa → PRRT → Capecitabine 1 (8.3)
SSa → Capecitabine → Temozolomide 1 (8.3)
SSa → 5- Fluorouracil+Epiribicin+Temozolomide →PRRT 1 (8.3)
Cisplatin+Etoposide → Temozolomide → Paclitaxel 1 (8.3)
Carboplatin+Etoposide → Oxaliplatin+5- Fluorouracil 
→ 5- Fluorouracil+Irinotecan
1 (8.3)
Cisplatin+Etoposide → SSa → PRRT 1 (8.3)
SSa → Cisplatin+Etoposide → PRRT 1 (8.3)
SSa → PRRT → Capecitabine+Bevacizumab 1 (8.3)
SSa → Capecitabine → PRRT 1 (8.3)
Oxaliplatin+Capecitabine → SSa → PRRT 1 (8.3)
Patients treated with fifth- line everolimus 
 (*administrated together with SSa in 1 patient)
6 (5.1)
Prior treatments 6 (100.0)
SSa 6 (100.0)
PRRT 6 (100.0)
CHT 1 (16.6)
SSa → 5- Fluorouracil → PRRT → Capecitabine 1 (16.6)
SSa → Cisplatin+Etoposide → PRRT → Capecitabine 1 (16.6)
SSa → Cisplatin+Etoposide → PRRT → 
Cisplatin+Etoposide
1 (16.6)
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The Kaplan–Meier analysis showed a trend toward better 
OS (P = 0.7401) in patients that experienced neither dose 
reduction nor dose delay (median OS not reached), fol-
lowed by patients that experienced only dose delay (median 
OS not reached), than patients with only dose reduction 
(median OS = 124 months) and finally patients that 
experienced both dose reduction and dose delay (median 
OS = 92 months).
Discussion
The aim of this study was to analyze clinical factors 
potentially influencing the global outcome of advanced 
PNET patients receiving everolimus in clinical practice in 
order to help clinicians in the decision- making process 
for the identification of treatment strategy in this 
setting.
The PI3K/Akt/mTOR pathway has been proved to be 
involved in the development and progression of PNETs 
[9, 17] with a high prevalence of mutation regarding 
nearly all the members of this molecular pathway 
[18–20].
On this basis, everolimus has been shown to be an 
effective therapeutic agent in these tumors [21, 22] since 
Yao et al. reported a significant improvement in PFS in 
patients treated with the mammalian target of rapamycin 
compared with placebo. This led to the introduction of 
this drug in the treatment strategy for advanced PNETs 
[10].
In this study, we investigated the prognostic role of 
CD and DI of everolimus in advanced PNETs achieving 
a median OS of 24 months (range: 2–42 months) in 
group A (CD ≤ 3000 mg), while in group B 
(CD > 3000 mg) it was not reached (HR: 26.9; 95% CI: 
11.0–76.7; P < 0.0001) (Fig. 2). Median PFS was 15 months 
(range: 0–57 months) and 23 months (range: 
Figure 1. Receiver operating characteristics analysis based on everolimus 
cumulative dose (CD) with death as end point. In this model, sensitivity 
was 78.6% (95% CI: 59.0–91.7) and specificity was 46.6% (95% CI: 
35.9–57.5). AUC was 0.642; P = 0.0124.
Figure 2. Overall survival stratified by the everolimus cumulative dose 
(CD):  ≤3000 mg (Group A) and  >3000 mg (Group B).
Figure 3. Progression- free survival stratified by the everolimus 
cumulative dose (CD):  ≤3000 mg (Group A) and  >3000 mg 
(Group B).
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0–71 months), respectively, in group A and B, with a 
significant advantage for this latter group (HR: 1.85; 95% 
CI: 1.141;2.996; P = 0.0125) (Fig. 3).
Furthermore, analysis of data showed that patients who 
maintained a DI higher than 9 mg/day experienced a 
significantly of longer OS and a trend to higher response 
rate, although not statistically significant.
Finally, this study confirms the independent prognostic 
role of stage of the disease, showing also a correlation 
with tumor grading.
Many clinical trials documented drug- related adverse 
events with everolimus, frequently leading to dose adjust-
ments or treatment interruption [10, 23], therefore, lower 
CD and DI of everolimus are administrated, with potential 
negative effects on patients’ outcomes.
The safety profile of everolimus has been proved to 
be generally acceptable in PNET patients, with severe 
toxicities occurring only in a tiny minority of subjects 
[24]. The onset of adverse events seems to be not cor-
related with the presence of liver metastasis, while previous 
treatment might affect the tolerability of this drug [25].
Furthermore, the onset of toxicities, especially mucositis, 
appear to be correlated with a major disease control rate 
(DCR) [24] and a longer PFS [26], as already known for 
other targeted agents used in the management of PNETs 
[27].
To the best of our knowledge, this study is the first 
to investigate the prognostic significance of CD and DI 
of everolimus in advanced PNETs.
Although the prolonged OS observed in patients with 
higher CD might be due to the fact that patients who 
maintain higher dose are usually better responsive to 
therapy, our results showed a significant correlation 
between CD and DI of everolimus and OS in a large 
series of patients with PNET, namely better prognosis in 
patients maintaining both higher CD and higher DI.
Furthermore, it is important to notice that patients in 
group B with a DI ≥ 9 mg/day presented a significantly 
in longer OS. This suggests that it could be more effec-
tive to maintain the full dose during the treatment, allow-
ing temporarily interruptions when necessary. Patients that 
experienced only dose delay showed a trend to higher 
OS if compared with patients with only dose reduction 
and patients with both dose reduction and dose delay.
The difference in OS in patients treated with everolimus 
seemed strictly dependent upon the CD taken by sensitive 
patients, thus suggesting that we should make the best 
efforts in order to manage toxicity without interrupting 
the treatment.
Dose delays and dose reductions with regard to amount 
reduced and length of delay may not directly translate 
into quantitative reductions in therapy intensity, so it 
could surely be interesting to determine a significant 
cut- off value for both dose delay and dose reduction. 
However, treatment duration was very heterogeneous 
among patients, and unavoidably conditioned by everoli-
mus efficacy, making difficult to identify a significant 
cut- off value.
Although selection bias and the retrospective nature of 
the study may have influenced our findings, overall present 
data seem to suggest that CD and DI potentially play a 
prognostic role for patients with advanced PNETs treated 
with everolimus.
This should prompt efforts to continue everolimus 
administration in responsive patients up to at least 3000 mg 
despite delays or temporary interruptions.
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